Fig. 8 | Scientific Reports

Fig. 8

From: Safety and biodistribution of intrathecal administration of mesenchymal stem cells (MSCs) and neurotrophin-releasing nanoparticles in a porcine CSF-guided delivery model for amyotrophic lateral sclerosis (ALS) drug discovery

Fig. 8

MRI visualization of intrathecal administration of mesenchymal stem/stromal cells (MSCs) and neurotrophin-releasing nanoparticles in pigs. Representative sagittal T2-weighted MRI images obtained at different stages of the experiment: (A) baseline scan before any intervention, showing normal spinal canal appearance without artefacts; (B) immediately after the first intrathecal administration of MSCs/NaCl, with arrows indicating the injection site and cerebrospinal fluid space; (C) one week after the second administration, showing no pathological signal changes; (D) after neurotrophin (NTs) administration, showing mild hypointense signal in the spinal canal corresponding to iron-labelled MSCs suspended in cerebrospinal fluid; (E) one week after the final procedure, showing complete normalization and absence of hypointense artefacts.

Back to article page